Ba A, Thiam L, Pouye M, Guo Y, Patel S, Sene S
medRxiv. 2024; .
PMID: 39484257
PMC: 11527082.
DOI: 10.1101/2024.10.13.24305808.
Bjornsson K, Bassi M, Knudsen A, Aves K, Morella Roig E, Sander A
Vaccines (Basel). 2024; 12(8).
PMID: 39203985
PMC: 11359962.
DOI: 10.3390/vaccines12080859.
Barrett J, Pipini D, Wright N, Cooper A, Gorini G, Quinkert D
Cell. 2024; 187(18):4964-4980.e21.
PMID: 39059380
PMC: 11380582.
DOI: 10.1016/j.cell.2024.06.015.
Williams B, King L, Pulido D, Quinkert D, Lias A, Silk S
Nat Commun. 2024; 15(1):4857.
PMID: 38849365
PMC: 11161584.
DOI: 10.1038/s41467-024-48721-3.
Dickey T, Tolia N
Trends Parasitol. 2024; 40(5):367-368.
PMID: 38604871
PMC: 11065576.
DOI: 10.1016/j.pt.2024.04.001.
The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for .
Takashima E, Otsuki H, Morita M, Ito D, Nagaoka H, Yuguchi T
Biomolecules. 2024; 14(1).
PMID: 38254700
PMC: 10813614.
DOI: 10.3390/biom14010100.
The PfRCR complex bridges malaria parasite and erythrocyte during invasion.
Farrell B, Alam N, Hart M, Jamwal A, Ragotte R, Walters-Morgan H
Nature. 2023; 625(7995):578-584.
PMID: 38123677
PMC: 10794152.
DOI: 10.1038/s41586-023-06856-1.
Designing an effective malaria vaccine targeting Plasmodium vivax Duffy-binding protein.
Dickey T, Tolia N
Trends Parasitol. 2023; 39(10):850-858.
PMID: 37481347
PMC: 11099547.
DOI: 10.1016/j.pt.2023.06.011.
The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals.
Tamborrini M, Schafer A, Hauser J, Zou L, Paris D, Pluschke G
Malar J. 2023; 22(1):210.
PMID: 37454145
PMC: 10349406.
DOI: 10.1186/s12936-023-04638-8.
Plasmepsin X activates the PCRCR complex of Plasmodium falciparum by processing PfRh5 for erythrocyte invasion.
Triglia T, Scally S, Seager B, Pasternak M, Dagley L, Cowman A
Nat Commun. 2023; 14(1):2219.
PMID: 37072430
PMC: 10113190.
DOI: 10.1038/s41467-023-37890-2.
Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine.
Dickey T, Gupta R, McAleese H, Ouahes T, Orr-Gonzalez S, Ma R
NPJ Vaccines. 2023; 8(1):20.
PMID: 36808125
PMC: 9938515.
DOI: 10.1038/s41541-023-00619-9.
sporozoites require the protein B9 to invade hepatocytes.
Fernandes P, Loubens M, Marinach C, Coppee R, Baron L, Grand M
iScience. 2023; 26(2):106056.
PMID: 36761022
PMC: 9906020.
DOI: 10.1016/j.isci.2023.106056.
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.
Healer J, Thompson J, Mackwell K, Browne C, Seager B, Ngo A
Front Cell Infect Microbiol. 2023; 12:1049065.
PMID: 36605129
PMC: 9807911.
DOI: 10.3389/fcimb.2022.1049065.
Pathogenicity and virulence of malaria: Sticky problems and tricky solutions.
Walker I, Rogerson S
Virulence. 2022; 14(1):2150456.
PMID: 36419237
PMC: 9815252.
DOI: 10.1080/21505594.2022.2150456.
Process development and preclinical evaluation of a major blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA).
Somanathan A, Mian S, Chaddha K, Uchoi S, Bharti P, Tandon R
Front Immunol. 2022; 13:1005332.
PMID: 36211427
PMC: 9535676.
DOI: 10.3389/fimmu.2022.1005332.
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate.
Ragotte R, Pulido D, Lias A, Quinkert D, Alanine D, Jamwal A
Nat Commun. 2022; 13(1):933.
PMID: 35177602
PMC: 8854392.
DOI: 10.1038/s41467-022-28601-4.
Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?.
Longoni S, Tiberti N, Bisoffi Z, Piubelli C
Front Med (Lausanne). 2021; 8:745665.
PMID: 34712683
PMC: 8545981.
DOI: 10.3389/fmed.2021.745665.
Plasmodium falciparum Cysteine-Rich Protective Antigen (CyRPA) Elicits Detectable Levels of Invasion-Inhibitory Antibodies during Natural Infection in Humans.
Mian S, Somanathan A, Chaddha K, Pandey A, Singh H, Krishna S
Infect Immun. 2021; 90(1):e0037721.
PMID: 34694918
PMC: 8788728.
DOI: 10.1128/IAI.00377-21.
Strain-Dependent Inhibition of Erythrocyte Invasion by Monoclonal Antibodies Against CyRPA.
Knudsen A, Bjornsson K, Bassi M, Walker M, Kok A, Cristinoi B
Front Immunol. 2021; 12:716305.
PMID: 34447381
PMC: 8383283.
DOI: 10.3389/fimmu.2021.716305.
Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.
Willcox A, Huber A, Diouf A, Barrett J, Silk S, Pulido D
Cell Rep Med. 2021; 2(7):100326.
PMID: 34337556
PMC: 8324462.
DOI: 10.1016/j.xcrm.2021.100326.